Nuevas opciones terapeúticas en el síndrome SHAPOfármacos anti-TFN-á

  1. Arias Santiago, Salvador
  2. Aneiros Fernández, José F.
  3. Girón Prieto, M.S.
  4. Martínez Peinado, C. M.
  5. Naranjo Sintes, Ramón
Revista:
Actualidad médica

ISSN: 0365-7965

Año de publicación: 2010

Tomo: 95

Número: 781

Páginas: 46-49

Tipo: Artículo

Otras publicaciones en: Actualidad médica

Resumen

El síndrome SAPHO se caracteriza por la presencia de manifestaciones ostoarticulares junto con lesiones cutáneas diversas como acné, psoriasis pustulosa y pustulosis palmoplantar. Se han empleado diversos fármacos para el control de la enfermedad con resultados variados, recientemente se han introducido los anti-TNF-á, con buena respuesta de las manifestaciones cut áneas y osteoarticulares. Se discute la utilidad de estos nuevos fármacos para el tratamiento de esta patología.

Referencias bibliográficas

  • Bachmeyer C, Begon E, Blum L, Cerf I, Petitjean B, Vignon-Pennamen MD, et al. Overlapping neutrophilic dermatosis in a patient with SAPHO syndrome. Arch Dermatol. 2007 Feb;143:275-6.
  • Belostocki K, Pricop L, Redecha PB, Aydin A, Leff L, Harrison MJ, Salmon JE. Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:384-8.
  • Benhamou CL, Chamot AM, Kahn MF. Synovitisacne-pustulosis hyperostosis-osteomyelitis syndrome (Sapho): a new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 1988;6:109-12.
  • Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Le syndrome pustulose hyperostose osteite (SAPHO). Resultats d'une enquête nationale: 85 observations. Rev Rhum Mal Osteoartic 1987;54:187-196.
  • Favalli EG, Varenna M, Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheumatol 2005; 23:247–50.
  • Gerster JC, Lagier R, Livio JJ. Propionibacterium acnes in a spondylitis with palmoplantar pustulosis. Ann Rheum Dis 1990; 49:337–9.
  • Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffman O, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 1999;29:159-71.
  • Kahn MF, Khan MA. The SAPHO syndrome. Baillieres Clin. Rheumatol 1994;8:333–62.
  • Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S,Burmester GR, Sterry W, Worm M. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007 Mar;156:486-91.
  • Marshall H, Bromilow J, Thomas AL, Arden NK. Pamidronate: a novel treatment for the SAPHO syndrome? Rheumatology 2002;41:231–3.
  • Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 2006;45:730-3.
  • Matsumoto T, Kaneko T, Seto M, et al. The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis. Clin Appl Thromb Hemost. 2008;14:186-92.
  • Moll C, Hernández MV, Cañete JD, Gómez-Puerta JA, Soriano A, Collado A, Sanmartí R Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum. 2008 ;37:299-306.
  • Oliveira JP, Levy A, Morel P, Guibal F. Severe neutrophilia induced by infliximab for psoriasis. Br J Dermatol. 2008;158:200-1.
  • Olivieri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome. Exp Opin Investig Drugs 2006;15:1229-33.
  • Pay S, Musaback U, Erdem H et al. Chimerical anti-TNF-alpha, infliximab, inhibits neutrophil chemotaxis and production of reactive oxygen species by blocking the priming effect of mononuclear cells on neutrophils. Immunopharmacol Immunotoxicol 2005; 27:187–98.
  • Sladden MJ, Clarke PJ, Mitchell B. Infliximabinduced acne: report of a third case. Br J Dermatol. 2008 ;158:172.
  • Trotta F, La Corte R, Bajocchi G, Manicardi S. Hyperostosis and multifocal osteitis: a purely rheumatological subset of the SAPHO syndrome. Clin Exp Rheumatol 1990;8:401-5.
  • Vélez A, Moreno JC. Síndrome SAPHO. Piel. 1998;13: 389-395.
  • Wagner AD, Andresen J, Jendro MC, Hülsemann JL, Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum. 2002 Jul;46(7):1965-8.
  • Widmer M, Weishaupt D, Brühlmann P, Michel BA, Forster A. Infliximab in the treatment of SAPHO syndrome: clinical experience and MRI response. Ann Rheum Dis 2003; 62:250-1.
  • Wohl Y, Bergman R, Sprecher E, Brenner S. Stress in a casae of SAPHO syndrome. Cutis 2003;71:63-7.
  • Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.Am J Clin Dermatol. 2008;9:1-14.